How to Disperse Fumed Silica: Methods, Equipment and Common Mistakes

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Silica for Battery Separator: Benefits for Lithium-Ion and Lead-Acid Batteries
  • Keywords: ultrafine silica powder
  • Published: 2026-11-20 02:07:35
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
In the case of solvent-free processes, the main advantage is that it is not necessary to get rid of the solvent residue from the system at the conclusion of the process, and the concentration of the API can also be controlled [ 36, 37 ]. Techniques employed in this class comprise physical mixing, co-milling, and melt sorption methods. The simplest approach is physical mixing [ 37 ], where fast drug filling is possible without special equipment. During direct mixing of the mesoporous carrier and the drug, the silanol groups on the surface of the silica bind the drug molecules. Nonetheless, its application is limited because it can be used largely for water-soluble molecules [ 37, 56 ]. Another method is co-milling, during which the mixture of the API and the nanocarrier is milled together [ 36, 37, 56 ]. In the case of the melt sorption method, the mixture of the API and the carrier system is heated above the melting point of the API under continuous stirring, while the melt is absorbed into the pores [ 36, 37 ]. After that, the system is cooled under lowered pressure, so that the molecules will be in an amorphous state in the pores [ 36, 37 ]. Nevertheless, this technique cannot be used in the case of heat-sensitive materials, due to the considerable thermal decomposition [ 20 ]. Microwave radiation can also be used for melting [ 2, 36 ].

How to Buy Fumed Silica: Grade Selection, Sampling and Supplier Evaluation

What Is Hydrophilic Fumed Silica? Properties, BET Grades and Typical Uses
Katalin Kristó
5N Quartz Sand: Purity Specifications, Key Impurities and High-Tech Applications
Silica 99.99% (4N): Specifications, Impurity Limits and Applications
Ho et al. employed the Multiple-Path Particle Dosimetry (MPPD) model for aerosolization and determination of lung deposition of silver nanoparticles, which method may be broadened to other materials like mesoporous silica nanoparticles [ 87 ]. It suggests particle size (mean 18 nm), density, and generation approach as principal elements that determine aerosolization efficiency and inhaled dose. Simulations of airflow, diffusion, sedimentation, and impact through airway generations yield comparable alveolar deposition fractions for particles less than 100 nm in humans and rats. With the addition of species-specific parameters, such as respiratory rate, lung surface region, tidal volume, and finished with possible lobar- and airway-level analysis, the MPPD model makes realistic regional retention predictions. Given that mesoporous silica nanoparticles are of similar size and physicochemical properties, the same methodology can estimate their aerosolization and lung deposition. In summary, the MPPD model is a handy tool in the assessment of inhalation danger and in guiding the formulation of safer nanomaterials [ 87 ]. In another study, Ali et al. applied the MPPD model to simulate aerosolization and lung deposition of mesoporous silica nanoparticles [ 88 ]. Pre-characterized MSNs with pre-specified aerodynamic diameters were initially assessed through scanning mobility particle sizing to yield accurate size-distribution inputs. Asymmetric mouse airway geometry and physiological parameters such as respiratory rate, lung volume, and airflow were used in simulations that were approximated to provide a total lung deposition of about 45%, of which 37% was in the head, 27% in the tracheobronchial, and 36% in the pulmonary (alveolar) region. These predictions are in reasonable agreement with earlier in vivo findings, validating the model. MPPD analysis also indicated that smaller MSNs exhibit more alveolar deposition, with the larger particles being better in the upper airways. Through linking aerosolization efficiency (via size distribution and concentration) and regional deposition, this modeling approach orients optimization of nanoparticle size and generation techniques toward maximizing targeted lung delivery [ 88 ]. To achieve easier production of aerosols, the surface of nanoparticles is often provided with a polymer coating, thereby stabilizing their distribution and increasing dispersibility [ 56 ]. By lowering the particle size, deeper lung areas can be reached [ 25 ]. Particles smaller than 1 µm are capable of accumulating in the alveoli, but the ideal size range to achieve maximum efficiency is in the 200-500 nm range [ 25 ]. Nevertheless, another review cited that particle size in the range of 50-200 nm is ideal for maximizing drug localization by inhalation [ 89 ]. It has also been recommended that the perfect diameter is approximately 500 nm for phagocytosis by alveolar macrophages [ 89 ]. Li et al. nebulized PEI-PEG-coated MSNs (50 nm particle size) by standard nebulizers without compromising their structure, while keeping particles in their individual form within the water droplets [ 90 ]. The aerosol supplies convenient delivery of MSNs to all areas of the respiratory tract - nasal, tracheobronchial, and pulmonary - and they persist for a week following inhalation, mostly within alveolar macrophages. It offers intracellular targeted delivery of lung diseases without passing through the gastrointestinal and first-pass metabolism. In spite of decreased deep lung deposition in mice under nasal breathing, exposure is comparable to that of humans with inhalation. Toxicity tests revealed no tissue damage or inflammation, further supporting MSN inhalation as a safe and effective method for vast treatment of pulmonary diseases, feasible for clinical translation [ 90 ]. A study investigated the effect of surface chemistry on drug loading capacity, release kinetics, and antibiotic activity in pulmonary infections on S. aureus bacterial cultures [ 18 ]. The model drugs were isoniazid, rifampicin, and vancomycin. Remarkable absorption ability was observed only with thiol (-SH) grafted carriers for all the tested drugs [ 18 ]. The in vitro drug release study showed sustained, but limited release: the cumulative release of rifampicin was 78.5% after 12 days, estimated by antibiogram [ 18 ]. Interestingly, the MIC values of the MSN-drug complex were higher for the free drug, probably due to the delayed and incomplete release from the pores [ 18 ]. Wang et al. developed a polydopamine-coated MSN formulation co-loaded with Ziyuglycoside I and Oseltamivir for the treatment of viral pneumonia. Interestingly, in vitro and in vivo studies have demonstrated that this carrier provided immediate release of Oseltamivir (allows quick virus killing) but prolonged release of Ziyuglycoside I (cuts down the inflammatory response for a longer period) [ 62 ].
Silica as a Polishing Agent: How It Works and Where It Is Used

How to Modify Nano Silica: Surface Modification Methods and Silane Selection

What is silica (SiO₂)?

microsilica for cement 95. Sun W.J., Aburub A., Sun C.C. A mesoporous silica based platform to enable tablet formulations of low dose drugs by direct compression. Int. J. Pharm. 2018;539:184-189. doi: 10.1016/j.ijpharm.2018.01.049. [ DOI ] [ PubMed ] [ Google Scholar ]

What is the difference between fumed silica and precipitated silica?

TEOS

What drives silica raw material prices?

fused silica CAS 60676-86-0

Cite this article: Silica Raw Materials News. "How to Get a Free Silica Sample: What to Request and How to Test It ." Published 2026-11-20 02:07:35. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.